Friday 6 November 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
103.93
19.03
−15.48%
Follow HALO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| 216.38% | 173.67% | 99.40% | 153.59% | ||
| 17.05% | 17.86% | 14.33% | 13.81% | ||
ROIC |
19.87% | 18.13% | 15.64% | 14.31% | |
Return on Tangible Assets |
33.41% | 61.47% | 48.31% | 43.39% | |
Average Days of Receivables |
106.43 | 100.00 | 110.82 | 115.33 | |
Free Cash Flow per Share |
7.89 | 6.87 | 5.65 | 5.38 | |
Free Cash Flow |
898.27 | 806.22 | 667.65 | 644.59 | |
Capital Expenditures |
— | (12.37) | (9.76) | (6.97) | |
| Other line items | |||||
Cash ROIC |
21.04% | 31.98% | 24.89% | 27.61% | |
Accounts Receivable Turnover |
4.14 | 4.31 | 3.96 | 3.73 | |
Accounts Payable Turnover |
13.07 | 13.83 | 15.19 | 14.69 | |
Inventory Turnover |
2.01 | 1.84 | 1.62 | 1.44 | |
Average Days of Payables |
38.30 | 29.47 | 19.82 | 33.34 | |
Days of Inventory on Hand |
151.43 | 171.17 | 218.58 | 281.56 | |
Tax Rate |
(0.26) | (0.29) | (0.31) | (0.32) | |
Research and Development Expense of Revenue |
22.07% | 23.28% | 25.00% | 26.23% | |
Selling, General and Administrative Expense of Revenue |
13.88% | 14.30% | 14.76% | 14.83% | |
Share Based Compensation of Revenue |
3.76% | 3.79% | 3.81% | 3.69% | |
Interest Coverage |
30.58 | 29.41 | 26.79 | 25.87 | |
Operating CF/Net income |
1.85 | 1.98 | 1.94 | 2.06 | |
Depreciation/Fixed assets |
0.00 | 1.45 | 1.31 | 1.12 | |
Capex/Depreciation |
— | (0.10) | (0.09) | (0.08) | |
Revenue per Share |
15.84 | 14.19 | 12.77 | 11.65 | |
Operating CF per Share |
7.89 | 6.98 | 5.73 | 5.44 | |
Capex per Share |
0.00 | (0.11) | (0.08) | (0.06) | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026